In summary, our findings shed more light on the impact of targeted therapy on the TME, as well as improve our understanding of how the immune cell infiltrate is altered upon continuous long-term exposure to TKI treatment and simultaneous administration of TKIs and ICB in EGFR-driven tumours. This evidence concerns the gene EGFR and neoplasm.